Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

M. Dreyling, W. Jurczak, M. Jerkeman, RS. Silva, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, SG. Cho, J. Bothos, JD. Goldberg, C. Enny, S. Traina, S. Balasubramanian, N. Bandyopadhyay, S....

. 2016 ; 387 (10020) : 770-8. [pub] 20151207

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16009899

E-zdroje NLK Online Plný text

ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy
PubMed 26673811
DOI 10.1016/s0140-6736(15)00667-4
Knihovny.cz E-zdroje

BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma. METHODS: This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 21 countries who had received one or more rituximab-containing treatments. Patients were stratified by previous therapy and simplified mantle-cell lymphoma international prognostic index score, and were randomly assigned with a computer-generated randomisation schedule to receive daily oral ibrutinib 560 mg or intravenous temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent 21-day cycles). Randomisation was balanced by using randomly permuted blocks. The primary efficacy endpoint was progression-free survival assessed by a masked independent review committee with the primary hypothesis that ibrutinib compared with temsirolimus significantly improves progression-free survival. The analysis followed the intention-to-treat principle. The trial is ongoing and is registered with ClinicalTrials.gov (number NCT01646021) and with the EU Clinical Trials Register, EudraCT (number 2012-000601-74). FINDINGS: Between Dec 10, 2012, and Nov 26, 2013, 280 patients were randomised to ibrutinib (n=139) or temsirolimus (n=141). Primary efficacy analysis showed significant improvement in progression-free survival (p<0·0001) for patients treated with ibrutinib versus temsirolimus (hazard ratio 0·43 [95% CI 0·32-0·58]; median progression-free survival 14·6 months [95% CI 10·4-not estimable] vs 6·2 months [4·2-7·9], respectively). Ibrutinib was better tolerated than temsirolimus, with grade 3 or higher treatment-emergent adverse events reported for 94 (68%) versus 121 (87%) patients, and fewer discontinuations of study medication due to adverse events for ibrutinib versus temsirolimus (9 [6%] vs 36 [26%]). INTERPRETATION: Ibrutinib treatment resulted in significant improvement in progression-free survival and better tolerability versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma. These data lend further support to the positive benefit-risk ratio for ibrutinib in relapsed or refractory mantle-cell lymphoma. FUNDING: Janssen Research & Development, LLC.

000      
00000naa a2200000 a 4500
001      
bmc16009899
003      
CZ-PrNML
005      
20160415110025.0
007      
ta
008      
160408s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(15)00667-4 $2 doi
024    7_
$a 10.1016/S0140-6736(15)00667-4 $2 doi
035    __
$a (PubMed)26673811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dreyling, Martin $u Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany. Electronic address: Martin.Dreyling@med.uni-muenchen.de.
245    10
$a Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study / $c M. Dreyling, W. Jurczak, M. Jerkeman, RS. Silva, C. Rusconi, M. Trneny, F. Offner, D. Caballero, C. Joao, M. Witzens-Harig, G. Hess, I. Bence-Bruckler, SG. Cho, J. Bothos, JD. Goldberg, C. Enny, S. Traina, S. Balasubramanian, N. Bandyopadhyay, S. Sun, J. Vermeulen, A. Rizo, S. Rule,
520    9_
$a BACKGROUND: Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma. METHODS: This randomised, open-label, multicentre, phase 3 clinical trial enrolled patients with relapsed or refractory mantle-cell lymphoma confirmed by central pathology in 21 countries who had received one or more rituximab-containing treatments. Patients were stratified by previous therapy and simplified mantle-cell lymphoma international prognostic index score, and were randomly assigned with a computer-generated randomisation schedule to receive daily oral ibrutinib 560 mg or intravenous temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent 21-day cycles). Randomisation was balanced by using randomly permuted blocks. The primary efficacy endpoint was progression-free survival assessed by a masked independent review committee with the primary hypothesis that ibrutinib compared with temsirolimus significantly improves progression-free survival. The analysis followed the intention-to-treat principle. The trial is ongoing and is registered with ClinicalTrials.gov (number NCT01646021) and with the EU Clinical Trials Register, EudraCT (number 2012-000601-74). FINDINGS: Between Dec 10, 2012, and Nov 26, 2013, 280 patients were randomised to ibrutinib (n=139) or temsirolimus (n=141). Primary efficacy analysis showed significant improvement in progression-free survival (p<0·0001) for patients treated with ibrutinib versus temsirolimus (hazard ratio 0·43 [95% CI 0·32-0·58]; median progression-free survival 14·6 months [95% CI 10·4-not estimable] vs 6·2 months [4·2-7·9], respectively). Ibrutinib was better tolerated than temsirolimus, with grade 3 or higher treatment-emergent adverse events reported for 94 (68%) versus 121 (87%) patients, and fewer discontinuations of study medication due to adverse events for ibrutinib versus temsirolimus (9 [6%] vs 36 [26%]). INTERPRETATION: Ibrutinib treatment resulted in significant improvement in progression-free survival and better tolerability versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma. These data lend further support to the positive benefit-risk ratio for ibrutinib in relapsed or refractory mantle-cell lymphoma. FUNDING: Janssen Research & Development, LLC.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antitumorózní látky $x škodlivé účinky $x terapeutické užití $7 D000970
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $x patologie $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a pyrazoly $x škodlivé účinky $x terapeutické užití $7 D011720
650    _2
$a pyrimidiny $x škodlivé účinky $x terapeutické užití $7 D011743
650    _2
$a recidiva $7 D012008
650    _2
$a sirolimus $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D020123
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jurczak, Wojciech $u Department of Hematology, Jagiellonian University, Krakow, Poland.
700    1_
$a Jerkeman, Mats $u Skånes Universitetssjukhus, Lund, Lund, Sweden.
700    1_
$a Silva, Rodrigo Santucci $u Instituto De Ensino E Pesquisa São Lucas, São Paulo, Brazil.
700    1_
$a Rusconi, Chiara $u Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
700    1_
$a Trneny, Marek $u Vseobecna fakultni nemocnice, Interni Klinika-Klinika Hematologie, Urologicka klinika, Prague, Czech Republic.
700    1_
$a Offner, Fritz $u UZ Gent-Departement Oncologie, Gent, Belgium.
700    1_
$a Caballero, Dolores $u Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain.
700    1_
$a Joao, Cristina $u Champalimaud Centre for the Unknown, Hematology Department, Lisbon, Portugal; Instituto Português de Oncologia, Lisbon, Portugal.
700    1_
$a Witzens-Harig, Mathias $u Klinikum der Ruprechts-Karls-Universität Heidelberg-Med. Klinik u. Poliklinik V, Heidelberg, Germany.
700    1_
$a Hess, Georg $u University Medical School of the Johannes Gutenberg-University, Department of Hematology, Oncology and Pneumology, Mainz, Germany.
700    1_
$a Bence-Bruckler, Isabelle $u The Ottawa Hospital-General Campus, Ottawa-Hospital General Campus, Ottawa, Canada.
700    1_
$a Cho, Seok-Goo $u Seoul St Mary's Hospital, Seocho-gu, Seoul, South Korea.
700    1_
$a Bothos, John $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Goldberg, Jenna D $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Enny, Christopher $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Traina, Shana $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Balasubramanian, Sriram $u Janssen Research & Development, LLC, Spring House, PA, USA.
700    1_
$a Bandyopadhyay, Nibedita $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Sun, Steven $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Vermeulen, Jessica $u Janssen Research & Development, LLC, Leiden, The Netherlands.
700    1_
$a Rizo, Aleksandra $u Janssen Research & Development, LLC, Raritan, NJ, USA.
700    1_
$a Rule, Simon $u Derriford Hospital, Plymouth, Devon, UK.
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 387, č. 10020 (2016), s. 770-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26673811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160415110110 $b ABA008
999    __
$a ok $b bmc $g 1113328 $s 934267
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 387 $c 10020 $d 770-8 $e 20151207 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace